Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Alexion Pharmaceuticals, Inc. (Sponsor)
- Phone Number: 1-855-752-2356
- Email: clinicaltrials@alexion.com
Study Locations
-
-
-
Le Kremlin-Bicêtre, France, 94270
- Research Site
-
-
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline.
- Presence of ADAs, with or without NAbs, irrespective of their titers.
- Confirmation by the TMB that both the clinical evidence and immunogenicity-mediated association noted above are present.
- Female participants of childbearing potential and male participants with partners of childbearing potential must follow protocol-specified contraception guidance as described in Section 10.5.
- Participant, or participant's legal guardian, is capable of signing informed consent or assent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol.
Exclusion Criteria:
- Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 [HIV 1, HIV 2] antibody) or hepatitis B or C viral infection.
- Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening.
- Inability of the participant, or the participant's legal guardian, to provide informed consent.
- Pregnant, breastfeeding, or intending to conceive during the course of the study.
- Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions).
- The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham [JC] virus), parvovirus, or Epstein Barr virus.
- The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis.
- The participant has had or is required to have any live vaccination within 1 month prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pediatric participants with HPP
Pediatric participants who have been receiving asfotase alfa treatment for their HPP, and who demonstrate immune-mediated LoE.
|
Methotrexate will be administered SC or orally weekly for 104 weeks.
Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
Bortezomib will be administered via IV bolus or SC, as needed.
IVIg will be administered via IV monthly through initial 74 weeks.
Folic acid will be given orally as long as methotrexate is being dosed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants Who Achieve Immunosuppressive Therapy (IST) Complete Response at Week 100
Time Frame: Week 100
|
Week 100
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number Participants with Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)
Time Frame: Baseline Through Week 100
|
Baseline Through Week 100
|
|
ADA and NAb Titer Levels
Time Frame: Baseline Through Week 100
|
Baseline Through Week 100
|
|
Serum Concentration of Asofatase Alfa (Measured as Enzyme Activity)
Time Frame: Baseline Through Week 100
|
Baseline Through Week 100
|
|
Plasma Concentration of Pyridoxal-5ˈ-Phosphate (PLP)
Time Frame: Baseline Through Week 100
|
Baseline Through Week 100
|
|
Plasma Concentration of Inorganic Pyrophosphates (PPi)
Time Frame: Baseline Through Week 100
|
Baseline Through Week 100
|
|
Number of Participants with Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events
Time Frame: Baseline Through Week 104
|
Baseline Through Week 104
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Metal Metabolism, Inborn Errors
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Hypophosphatasia
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Inorganic Chemicals
- Pterins
- Pteridines
- Aminopterin
- Immunoglobulin Isotypes
- Immunoglobulin G
- Antibodies, Monoclonal, Murine-Derived
- Boronic Acids
- Acids, Noncarboxylic
- Acids
- Boron Compounds
- Pyrazines
- Rituximab
- Bortezomib
- Methotrexate
- Folic Acid
- Immunoglobulins, Intravenous
Other Study ID Numbers
Other Study ID Numbers
- D8400C00001
- 2022-502793-17 (EudraCT Number)
- AA-HPP-407 (Other Identifier: Alexion)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.